Skip to main content

How to Prepare an Initial Public Offering 2016

Author(s): Robert A. Freedman, Sophia Hudson
Practice Area: Corporate & Securities
Published: Apr 2016
PLI Item #: 148882
CHB Spine #: B2235

Robert Freedman is co-chair of the Securities & Corporate Finance group and provides corporate and securities law services to late stage and public technology and life sciences companies. He leads initial public offerings and follow-on offerings of equity and debt, and focuses on advising boards and management on corporate and securities law compliance and disclosure matters. Rob has represented issuers and underwriters in securities offerings by public companies for over 20 years. Rob also concentrates on mergers and acquisitions and private financings for public companies.

Representative Clients:

  • Aeglea BioTherapeutics
  • AnaptysBio
  • Audentes Therapeutics
  • BioPharmX
  • Corium International
  • Concur Technologies
  • Data Domain
  • DexCom
  • Handspring
  • Keynetics
  • Loxo Oncology
  • Macromedia
  • Marvell Technology Group
  • Merrill Lynch & Co.
  • Opsware
  • OrbiMed Advisors
  • ProNAi Therapeutics
  • ServiceNow
  • Shutterfly
  • Silver Spring Networks
  • Thomas Weisel Partners
  • ZymoGenetics

Representative IPO Clients:

  • Aeglea BioTherapeutics
  • Castlight Health
  • Corium International
  • Cowen and Company
  • Dermira
  • DexCom
  • J.P. Morgan Securities
  • Loxo Oncology
  • Planet Payment
  • Piper Jaffray & Co.
  • ProNAi Therapeutics
  • ServiceNow
  • Shutterfly
  • Silver Springs Networks

Representative M&A and Tender Offer Experience:

  • DexCom acquisition of SweetSpot Diabetes Care
  •,’s acquisition by,
  • Alpha Innotech’s acquisition by Cell Biosciences
  • Data Domain’s acquisition by EMC
  • Cisco Systems’s acquisition of WebEx Communications
  • Macromedia’s merger with Adobe

Rob is admitted to practice only in California, Idaho and Washington. He received his A.B. degree in biochemistry and history in 1987 from Bowdoin College where he graduated summa cum laude and Phi Beta Kappa. He received his J.D. degree, with distinction, in 1993 from Stanford University.

In 2015, Robert was recommended by The Legal 500 for his individual practice and role as co-chair of Fenwick’s corporate and securities practice, which was recognized as a team of “highly knowledgeable and flexible technology sector specialists.”

Rob is the co-chair for the Practising Law Institute’s “How to Prepare an Initial Public Offering” program.

Prior to law school, Rob was a banker for Manufacturers Hanover Trust in New York.

Ms. Hudson is a partner in Davis Polk’s Corporate Department, practicing in the Capital Markets Group. She advises U.S. and non-U.S. issuers and underwriters on capital markets transactions, including initial public offerings and other equity offerings, public and private high-yield, investment-grade and convertible debt offerings and private placements of equity and convertible securities for early stage companies. She also advises her corporate clients, including management teams and boards of directors, on governance, corporate and securities law matters.

Her experience ranges across a variety of industries, including biotech, consumer, financials, industrials, mining, retail, specialty pharmaceuticals and technology.

She has represented all the major U.S. investment banks.


  • New York Law Journal – “Rising Star,” 2017
  • Law360 – “Rising Star," Life Sciences, 2016


  • Partnership for New York City, David Rockefeller Fellow, 2016-17
  • Co-Chair, Practising Law Institute’s “How to Prepare an Initial Public Offering,” 2015,  2016 and 2017


  • Partner, 2014-present
  • Associate, 2006-2014


  • State of New York


  • A.B., History, Princeton University, 2000
  • J.D., University of Michigan Law School, 2006
    • magna cum laude
    • Order of the Coif
    • Associate Editor, Michigan Law Review